4.8 Article

Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway

Journal

ELIFE
Volume 9, Issue -, Pages -

Publisher

eLIFE SCIENCES PUBL LTD
DOI: 10.7554/eLife.57761

Keywords

-

Categories

Funding

  1. Newton-Ungku Omar Fund
  2. Medical Research Council, United Kingdom [MR/P013457/1]
  3. Wellcome Trust [206194]
  4. Cancer Research Malaysia
  5. Wellcome
  6. MRC [MR/P013457/1] Funding Source: UKRI

Ask authors/readers for more resources

New therapeutic targets for oral squamous cell carcinoma (OSCC) are urgently needed. We conducted genome-wide CRISPR-Cas9 screens in 21 OSCC cell lines, primarily derived from Asians, to identify genetic vulnerabilities that can be explored as therapeutic targets. We identify known and novel fitness genes and demonstrate that many previously identified OSCC-related cancer genes are non-essential and could have limited therapeutic value, while other fitness genes warrant further investigation for their potential as therapeutic targets. We validate a distinctive dependency on YAP1 and WWTR1 of the Hippo pathway, where the lost-of-fitness effect of one paralog can be compensated only in a subset of lines. We also discover that OSCCs with WWTR1 dependency signature are significantly associated with biomarkers of favorable response toward immunotherapy. In summary, we have delineated the genetic vulnerabilities of OSCC, enabling the prioritization of therapeutic targets for further exploration, including the targeting of YAP1 and WWTR1.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists

Vera Grinkevitch, Mark Wappett, Nyree Crawford, Stacey Price, Andrea Lees, Christopher McCann, Katherine McAllister, Jochen Prehn, Jamie Young, Jess Bateson, Lewis Gallagher, Magali Michaut, Vivek Iyer, Aikaterini Chatzipli, Syd Barthorpe, Daniel Ciznadija, Ido Sloma, Amy Wesa, David A. Tice, Lodewyk Wessels, Mathew Garnett, Daniel B. Longley, Ultan McDermott, Simon S. McDade

Summary: Second-generation TRAIL-R2 agonists face two major clinical challenges: lack of predictive biomarkers and development of resistance. This study identifies caspase-8:FLIP(L) and caspase-8:MCL-1 ratios as potential predictive biomarkers for second-generation TRAIL-R2 agonists, and loss of key effectors like FADD and caspase-8 as likely drivers of clinical resistance in solid tumors.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Biochemistry & Molecular Biology

Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor-positive breast cancer

Heather M. Brechbuhl, Mengyu Xie, Etana G. Kopin, Amy L. Han, Kiran Vinod-Paul, Jaime Hagen, Susan Edgerton, Philip Owens, Sharon Sams, Anthony Elias, Carol A. Sartorius, Aik-Choon Tan, Peter Kabos

Summary: The tumor microenvironment plays a crucial role in response and resistance to endocrine therapy in ER-positive breast cancer. The study found that neoadjuvant endocrine therapy alters TME composition, promoting the expansion of less favorable TASC(CDCP1) population associated with TME remodeling and increased immune infiltration supportive of tumor progression.

MOLECULAR CARCINOGENESIS (2022)

Article Multidisciplinary Sciences

ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer

Marco Napoli, Sarah J. Wu, Bethanie L. Gore, Hussein Abbas, Kyubum Lee, Rahul Checker, Shilpa Dhar, Kimal Rajapakshe, Aik Choon Tan, Min Gyu Lee, Cristian Coarfa, Elsa R. Flores

Summary: Distinct lung stem cells regulated by increment Np63 play a role in the development of both lung adenocarcinoma and squamous cell carcinoma through the regulation of a common landscape of enhancer-associated genes, including BCL9L.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer

Anna Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Vladimir Poroshin, Michael Ughetto, Matthew J. Martin, Hannah Thorpe, Aurelie Bornot, Paul D. Smith, Ben Sidders, Jonathan R. Dry, Miika Ahdesmaki, Ultan McDermott, Eliseo Papa, Krishna C. Bulusu

Summary: Resistance to EGFR inhibitors is a major challenge in the treatment of non-small cell lung cancer. The authors developed a recommender system that ranks genes based on diverse types of evidence, identifying potential mechanisms of EGFR inhibitor resistance.

NATURE COMMUNICATIONS (2022)

Correction Multidisciplinary Sciences

Author Correction: ΔNp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer (vol 13, 614, 2022)

Marco Napoli, Sarah J. Wu, Bethanie L. Gore, Hussein A. Abbas, Kyubum Lee, Rahul Checker, Shilpa Dhar, Kimal Rajapakshe, Aik Choon Tan, Min Gyu Lee, Cristian Coarfa, Elsa R. Flores

NATURE COMMUNICATIONS (2022)

Article Oncology

Pan-cancer proteomic map of 949 human cell lines

Emanuel Goncalves, Rebecca C. Poulos, Zhaoxiang Cai, Syd Barthorpe, Srikanth S. Manda, Natasha Lucas, Alexandra Beck, Daniel Bucio-Noble, Michael Dausmann, Caitlin Hall, Michael Hecker, Jennifer Koh, Howard Lightfoot, Sadia Mahboob, Iman Mali, James Morris, Laura Richardson, Akila J. Seneviratne, Rebecca Shepherd, Erin Sykes, Frances Thomas, Sara Valentini, Steven G. Williams, Yangxiu Wu, Dylan Xavier, Karen L. MacKenzie, Peter G. Hains, Brett Tully, Phillip J. Robinson, Qing Zhong, Mathew J. Garnett, Roger R. Reddel

Summary: The study analyzes the proteomes of multiple cancer cell lines through mass spectrometry and reveals thousands of cancer protein biomarkers that are not significant at the transcript level, demonstrating that the proteome has predictive power for drug response similar to the transcriptome.

CANCER CELL (2022)

Article Biochemistry & Molecular Biology

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma

Samuel Coleman, Mengyu Xie, Ahmad A. Tarhini, Aik Choon Tan

Summary: Immunotherapy has made significant advancements in the treatment of melanoma, but there is still a need for predictive biomarkers to select patients for immune checkpoint inhibitors (ICIs) therapy. This study evaluated previously published predictive biomarkers based on gene expression signatures and found that biomarkers related to IFN-gamma-responsive genes, T and B cell markers, and chemokines in the tumor immune microenvironment can predict the response to ICIs. The study also showed that these biomarkers are more predictive in on-treatment samples compared to pretreatment samples in metastatic melanoma.

MOLECULAR CARCINOGENESIS (2023)

Article Cell Biology

Advanced age is associated with changes in alveolar macrophages and their responses to the stress of traumatic injury

Devin M. Boe, Holly J. Hulsebus, Kevin M. Najarro, Juliet E. Mullen, Hyunmin Kim, Aik Choon Tan, Rachel H. McMahan, Elizabeth J. Kovacs

Summary: As individuals age, alveolar macrophages (AMs) in the lower airways undergo various changes in phenotype and function, exhibiting characteristics of cellular senescence and reduced response to physiological stressors. These age-related alterations, potentially involving glucocorticoid-regulated genes, could interfere with AMs' responses to stressors and contribute to their dysfunction during healthy aging.

JOURNAL OF LEUKOCYTE BIOLOGY (2022)

Article Oncology

Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma

Sofia Birkealv, Mark Harland, Larissa Satiko Alcantara Sekimoto Matsuyama, Mamun Rashid, Ishan Mehta, Jonathan P. Laye, Kerstin Haase, Tracey Mell, Vivek Iyer, Carla Daniela Robles-Espinoza, Ultan McDermott, Peter van Loo, Marieke L. Kuijjer, Patricia A. Possik, Silvya Stuchi Maria Engler, D. Timothy Bishop, Julia Newton-Bishop, David J. Adams

Summary: This study conducted sequence profiling of 524 American Joint Committee on Cancer Stage I-III primary tumors, revealing recurrent driver mutations, mutually exclusive genetic interactions, and an absence of co-occurring genetic events. By intersecting copy number calls with CRISPR screening data, the transcription factor IRF4 was identified as a melanoma-associated dependency.

JOURNAL OF PATHOLOGY (2023)

Article Biochemistry & Molecular Biology

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates

Claudia Buhigas, Anne Y. Warren, Wing-Kit Leung, Hayley C. Whitaker, Hayley J. Luxton, Steve Hawkins, Jonathan Kay, Adam Butler, Yaobo Xu, Dan J. Woodcock, Sue Merson, Fiona M. Frame, Atef Sahli, Federico Abascal, Inigo Martincorena, G. Steven Bova, Christopher S. Foster, Peter Campbell, Norman J. Maitland, David E. Neal, Charlie E. Massie, Andy G. Lynch, Rosalind A. Eeles, Colin S. Cooper, David C. Wedge, Daniel S. Brewer

Summary: This study suggests that cells within normal prostate tissue can expand through mechanisms distinct from cancer, likely originating from stromal cells. Compared to cancer, normal tissue has fewer single nucleotide variants, almost no structural variants or copy number alterations. These findings have significant implications for treatment and early detection approaches.

MOLECULAR CANCER (2022)

Article Cell Biology

Drepmel-A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment

Zachary J. Thompson, Jamie K. Teer, Jiannong Li, Zhihua Chen, Eric A. Welsh, Yonghong Zhang, Noura Ayoubi, Zeynep Eroglu, Aik Choon Tan, Keiran S. M. Smalley, Yian Ann Chen

Summary: DRepMel is a Shiny app developed to provide rational combination treatment predictions for melanoma patients using a multi-omics drug repurposing computational approach. It offers robust predictions based on whole exome sequencing and RNA-seq data, and also identifies potential treatment effects on the tumor microenvironment using single-cell RNA-seq data.

CELLS (2022)

Article Genetics & Heredity

Deciphering the Tumor-Immune-Microbe Interactions in HPV-Negative Head and Neck Cancer

Min Hu, Samuel Coleman, Muhammad Zaki Hidayatullah Fadlullah, Daniel Spakowicz, Christine H. Chung, Aik Choon Tan

Summary: Patients with human papillomavirus-negative head and neck squamous cell carcinoma (HPV-negative HNSCC) have worse outcomes than HPV-positive HNSCC. In our study, we found that microbial signatures can distinguish Hypoxia/Immune phenotypes similar to gene expression signatures in molecularly classified tumor groups. Additionally, we identified three highly-correlated microbes that are crucial for immunotherapy response in immune processes. The co-abundance of these three microbes significantly affects the survival of patients in a molecularly heterogenous group.

GENES (2023)

Article Biochemistry & Molecular Biology

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

Francesco Orlando, Alessandro Romanel, Blanca Trujillo, Michael Sigouros, Daniel Wetterskog, Orsetta Quaini, Gianmarco Leone, Jenny Z. Xiang, Anna Wingate, Scott Tagawa, Anuradha Jayaram, Mark Linch, Mariam Jamal-Hanjani, Charles Swanton, Mark A. Rubin, Alexander W. Wyatt, Himisha Beltran, Gerhardt Attard, Francesca Demichelis

Summary: Sequencing of cell-free DNA in cancer patients' plasma can detect tumor cell genomic alterations and aid clinical decision-making. The novel detection strategy, PCF SELECT, shows improved detection of genomic alterations in samples with low tumor fractions. More extensive pan-genome allelic imbalance was identified in plasma samples from prostate cancer patients.

NAR CANCER (2022)

Meeting Abstract Oncology

Predictors of immunotherapeutic benefits in patients with advanced melanoma and other malignancies treated with immune checkpoint inhibitors utilizing ORIEN real-world data

Ahmad A. Tarhini, Aik Choon Tan, Mengyu Xie, Issam El Naqa, Payman Ghasemi Saghand, Donghai Dai, James Lin Chen, Aakrosh Ratan, Martin McCarter, John D. Carpten, Howard Colman, Alexandra Ikeguchi, Abhishek Tripathi, Igor Puzanov, Susanne M. Arnold, Michelle L. Churchman, Patrick Hwu, Jose Conejo-Garcia, William S. Dalton, George J. Weiner

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

A deep learning approach utilizing clinical and molecular data for identifying prognostic biomarkers in patients treated with immune checkpoint inhibitors: An ORIEN pan-cancer study

Payman Ghasemi Saghand, Issam El Naqa, Aik Choon Tan, Mengyu Xie, Donghai Dai, James Lin Chen, Aakrosh Ratan, Martin McCarter, John D. Carpten, Harsh Shah, Alexandra Ikeguchi, Abhishek Tripathi, Igor Puzanov, Susanne M. Arnold, Michelle L. Churchman, Patrick Hwu, Jose Conejo-Garcia, William S. Dalton, George J. Weiner, Ahmad A. Tarhini

JOURNAL OF CLINICAL ONCOLOGY (2022)

No Data Available